Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Ribociclib Given Concurrently with Postoperative Radiation Therapy for the Treatment of Patients with High-Risk, Node Positive, Hormone Receptor Positive, HER2 Negative Breast Cancer

Trial Status: active

This phase I trial tests the safety, side effects and best dose of ribociclib given during (concurrently) postoperative radiation therapy for the treatment of patients with high risk, lymph node positive, hormone receptor positive, HER2 negative breast cancer. Ribociclib is in a class of medications called kinase inhibitors. It works by blocking the signals that cause tumor cells to multiply. This helps to stop the spread of tumor cells. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Giving ribociclib concurrently with postoperative radiation therapy may be safe and effective in treating patients with high risk, node positive, hormone receptor positive, HER2 negative breast cancer.